根据 CAPItello-291 试验的结果，卡匹色替已在美国、欧盟、日本、中国及其他几个国家获得批准，用于治疗 HR 阳性、HER2 ...

Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell ...